Article Rich Health Growing Incidences of Diabetes to drive the Fibrinogen Testing Market

Growing Incidences of Diabetes to drive the Fibrinogen Testing Market

According to PersistenceMarketResearch, the global fibrinogen testing market will grow at the rate of over 8% between 2020 and 2030.

Fibrinogen Testing”, better known as “Factor I Assay”, determines the level of blood plasma protein in the blood. It gets formed in liver. A point to note herein is that fibrinogen is amongst the 13 coagulation factors that hold responsibility of proper blood clotting. This, in other words, states that deficiency of fibrinogen obstructs the clotting process, thereby resulting in excessive bleeding.

At times, low levels of fibrinogen could also result in blood clot being formed unnecessarily in the blood vessel. It is termed as “thrombosis”. This blockage of blood flow could result in severe medical conditions like stroke and cardiac arrest.

The medical practitioner is likely to advise fibrinogen testing in wake of excessive bruising, frequent nosebleeds, gums bleeding profusely, haemorrhage regarding gastrointestinal tract, blood in stool, blood in urine, bleeding head, and spleen being ruptured.

Get the sample copy of article:

Also, incidences of chronic diseases like diabetes are increasing at a substantial rate. The CDC states that close to 30 Mn people are diabetic all across the US. This accounts for close to 10% of the entire population of the US. It is a known fact that diabetes does complicate blood clotting as blood-flow gets prevented even in case of small injuries. This factor is bound to catalyse the fibrinogen testing market in the forecast period.

Out of Europe, North America, APAC, MEA, and LATAM, North America is the major revenue generator, followed by the Europe due to immediate adoption of fibrinogen testing herein. The Asia-Pacific is expected to grow at the rapid pace going forward due to it being home to more than 60% of diabetic population and rising awareness regarding the same.

The key market participants include Thermo Fisher Scientific Inc., Werfen, Tulip Diagnostics (P) Ltd., Diagnostica Stago S.A.S., Helena Laboratories Corporation, Grifols S.A., and Siemens Healthcare GmbH.